Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508340 | 0.89 | HTR7 (0.59) | PRKCIFFAR1HTR7MAP2K4CNR2 | |
| SCHEMBL205233 | 0.87 | CNR2 (0.48) | PRKCIFFAR1HTR7MAP2K4CNR2 | |
| SCHEMBL12640964 | 0.82 | CYP11B1 (0.43) | PRKCIFFAR1HTR7MAP2K4CNR2 | |
| SCHEMBL28011375 | 0.82 | FGFR1 (0.49) | PRKCIFFAR1HTR7CNR2NR1H2 | |
| SCHEMBL12577779 | 0.82 | PRKCI (0.42) | PRKCIFFAR1HTR7MAP2K4CNR2 | |
| SCHEMBL12577791 | 0.81 | HTR7 (0.51) | PRKCIFFAR1HTR7MAP2K4CNR2 | |
| SCHEMBL28853922 | 0.80 | FYN (0.46) | PRKCIFFAR1HTR7MAP2K4CNR2 | |
| SCHEMBL16219594 | 0.80 | HTR7 (0.41) | FFAR1HTR7 | |
| SCHEMBL5101705 | 0.79 | MEN1 (0.44) | PRKCIFFAR1HTR7CNR2 | |
| SCHEMBL28011376 | 0.79 | CNR2 (0.48) | PRKCIFFAR1HTR7MAP2K4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | GPR119, GPR55, GLP1R | PRKCI 2010/4885FFAR1 5/4885HTR7 825/4885 |
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | PRKCI 4633/4885FFAR1 93/4885HTR7 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.